There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
OBJECTIVE To assess prevention of bone mineral density ( BMD ) loss and durability of the response during treatment with prasterone in women with systemic lupus erythematosus ( SLE ) receiving chronic glucocorticoids . METHODS 155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase . Subsequently , 114 patients were re-r and omized to receive 200 or 100 mg/day prasterone for 12 months in an open-label phase . Primary efficacy endpoints were changes in BMD at the lumbar spine ( L-spine ) from baseline to Month 6 and maintenance of BMD from Month 6 to 18 for patients who received prasterone during the double-blind phase . RESULTS In the double-blind phase , there was a trend for a small gain in BMD at the L-spine for patients who received 200 mg/day prasterone for 6 months versus a loss in the placebo group ( mean + /- SD , 0.003 + /- 0.035 vs -0.005 + /- 0.053 g/cm(2 ) , respectively ; p = 0.293 between groups ) . In the open-label phase , there was dose-dependent increase in BMD at the L-spine at Month 18 between patients who received 200 versus 100 mg/day prasterone ( p = 0.021 ) . For patients who received 200 mg/day prasterone for 18 months , the L-spine BMD gain was 1.083 + /- 0.512 % ( p = 0.042 ) . There was no overall change in BMD at the total hip over 18 months with 200 mg/day prasterone treatment . The safety profile reflected the weak and rogenic properties of prasterone . CONCLUSION This study suggests prasterone 200 mg/day may offer mild protection against bone loss in women with SLE receiving glucocorticoids . ( Clinical Trials.gov Identifiers NCT00053560 and NCT00082511 )
There is no evidence that DHEA  improves quality of life but there is some evidence that it is associated with and rogenic side effects .
There is uncertainty whether DHEA decreases menopausal symptoms , but DHEA may slightly improve sexual function compared with placebo
BACKGROUND During menopause a decreasing ovarian follicular response generally causes a fluctuation and eventual decrease in estrogen levels .
This can lead to the development of various perimenopausal and postmenopausal symptoms ( for example hot flushes , night sweats , vaginal dryness ) .
Dehydroepi and rosterone ( DHEA ) is one of the main precursors of and rogens , which in turn are converted to testosterone and estrogens .
It is possible that the administration of DHEA may increase estrogen and testosterone levels in peri- and postmenopausal women to alleviate their symptoms and improve general wellbeing and sexual function ( for example libido , dyspareunia , satisfaction ) .
Treatment with DHEA is controversial as there is uncertainty about its effectiveness and safety .
This review should clearly outline the evidence for DHEA in the treatment of menopausal symptoms and evaluate its effectiveness and safety by combining the results of r and omised controlled trials .
OBJECTIVES To assess the effectiveness and safety of administering DHEA to women with menopausal symptoms in the peri- or postmenopausal phase .